Krystal Biotech (KRYS) net assets (shareholders' equity)

Net assets · fiscal 2025
$1.22B

Krystal Biotech (KRYS) had net assets of $1.22B at the end of fiscal 2025 (December 31, 2025). That is 28.9% higher than the $946.38M of fiscal 2024. Figures as of 19 Nov 2026, 11:29 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$1.22B
Change on fiscal 2024
+28.9%
Growth, 5 years
+33.1% a year
Highest on record
$1.22Bfiscal 2025
Lowest on record
$289.00Kfiscal 2016
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Krystal Biotech net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 33.1% a year. Across the 10 fiscal years on record (2016–2025), the highest was $1.22B in fiscal 2025 and the lowest $289.00K in fiscal 2016.

History · 10 fiscal years

Net assets by fiscal year

Krystal Biotech net assets (shareholders' equity), year by year

Krystal Biotech (KRYS) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$1.22B 28.9% up
2024$946.38M 21.5% up
2023$778.64M 49.1% up
2022$522.23M 12.0% down
2021$593.58M 103.2% up
2020$292.08M 43.9% up
2019$202.91M 79.2% up
2018$113.23M 128.9% up
2017$49.47M 17,019.0% up
2016$289.00K—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Krystal Biotech and comparable companies
CompanyNet assetsFiscal year
Praxis Precision Medicines PRAX$878.14M2025
Twist Bioscience TWST$888.02M2026
Protagonist Therapeutics PTGX$614.71M2025
Krystal Biotech KRYS$1.22B2025
10x Genomics TXG$796.33M2025
HealthEquity HQY$2.11B2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KRYS

Krystal Biotech, figure by figure

Krystal Biotech (KRYS) overview: price, valuation and scorecardAll health care companies by market value

Krystal Biotech net assets (shareholders' equity): questions and answers

What are Krystal Biotech's net assets?

Krystal Biotech (KRYS) had net assets of $1.22B at the end of fiscal 2025 (December 31, 2025). That is 28.9% higher than the $946.38M of fiscal 2024.

What is the growth rate of Krystal Biotech's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 33.1% a year.

What are the highest and lowest net assets figures on record for Krystal Biotech?

Across the 10 fiscal years on record (2016–2025), the highest was $1.22B in fiscal 2025 and the lowest $289.00K in fiscal 2016.

How is Krystal Biotech's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Krystal Biotech it is on record here for 10 fiscal years, 2016 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Krystal Biotech (KRYS) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/KRYS/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.